{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:01:42Z","timestamp":1749751302580},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"DOI":"10.7759\/cureus.31977","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:33:51Z","timestamp":1669653231000},"source":"Crossref","is-referenced-by-count":2,"title":["Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab"],"prefix":"10.7759","author":[{"given":"Ludovic","family":"Saba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Bari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli F","year":"2018","unstructured":"Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018, 32:223-40. 10.1016\/j.berh.2018.08.005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore Y","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J. Systemic sclerosis. Nat Rev Dis Primers. 2015, 1:15002. 10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen FH","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996, 35:364-72. 10.1093\/rheumatology\/35.4.364","journal-title":"Br J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai M","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012, 51:1017-26. 10.1093\/rheumatology\/ker269","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich DJ","year":"1989","unstructured":"Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989, 32:1128-34. 10.1002\/anr.1780320911","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198311000-00001","article-title":"Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases","volume":"62","author":"Traub YM","year":"1983","unstructured":"Traub YM, Shapiro AP, Rodnan GP, et al.. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983, 62:335-52. 10.1097\/00005792-198311000-00001","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle NS","year":"2015","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015, 6:257. 10.3389\/fimmu.2015.00257","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00036","article-title":"Early components of the complement classical activation pathway in human systemic autoimmune diseases","volume":"7","author":"Lintner KE","year":"2016","unstructured":"Lintner KE, Wu YL, Yang Y, et al.. Early components of the complement classical activation pathway in human systemic autoimmune diseases. Front Immunol. 2016, 7:36. 10.3389\/fimmu.2016.00036","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90986-0","article-title":"Factors predicting development of renal involvement in progressive systemic sclerosis","volume":"76","author":"Steen VD","year":"1984","unstructured":"Steen VD, Medsger TA Jr, Osial TA Jr,  Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984, 76:779-86. 10.1016\/0002-9343(84)90986-0","journal-title":"Am J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler EA","year":"2019","unstructured":"Butler EA, Baron M, Fogo AB, et al.. Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology. Arthritis Rheumatol. 2019, 71:964-71. 10.1002\/art.40809","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann BC","year":"2006","unstructured":"Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006, 11:694-703. 10.1634\/theoncologist.11-6-694","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j M","year":"2016","unstructured":"Okr\u00f3j M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016, 18:267. 10.1186\/s13075-016-1168-x","journal-title":"Arthritis Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2008.268","article-title":"[Hypocomplementemia in systemic sclerosis]","volume":"60","author":"Cuomo G","year":"2008","unstructured":"Cuomo G, Abignano G, Ruocco L, Vettori S, Valentini G. [Hypocomplementemia in systemic sclerosis]. Reumatismo. 2008, 60:268-73. 10.4081\/reumatismo.2008.268","journal-title":"Reumatismo"},{"key":"ref14","article-title":"Hypocomplementemia in systemic sclerosis--clinical and serological correlations","volume":"34","author":"Hudson M","year":"2007","unstructured":"Hudson M, Walker JG, Fritzler M, Taillefer S, Baron M. Hypocomplementemia in systemic sclerosis--clinical and serological correlations. J Rheumatol. 2007, 34:2218-23.","journal-title":"J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal I","year":"2009","unstructured":"Batal I, Domsic RT, Shafer A, Medsger TA Jr, Kiss LP, Randhawa P, Bastacky S. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009, 40:332-40. 10.1016\/j.humpath.2008.08.001","journal-title":"Hum Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114856","article-title":"The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study","volume":"10","author":"Scambi C","year":"2015","unstructured":"Scambi C, Ugolini S, Jokiranta TS, et al.. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study. PLoS One. 2015, 10:e0114856. 10.1371\/journal.pone.0114856","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10257","article-title":"Targeted therapy in systemic sclerosis","volume":"7","author":"Baron M","year":"2016","unstructured":"Baron M. Targeted therapy in systemic sclerosis. Rambam Maimonides Med J. 2016, 7:10.5041\/RMMJ.10257","journal-title":"Rambam Maimonides Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse A","year":"2016","unstructured":"Devresse A, Aydin S, Le Quintrec M, et al.. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore). 2016, 95:e4459. 10.1097\/MD.0000000000004459","journal-title":"Medicine (Baltimore)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6051083","article-title":"Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab","volume":"2018","author":"Uriarte MH","year":"2018","unstructured":"Uriarte MH, Larrarte C, Rey LB. Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab. Case Rep Nephrol. 2018, 2018:6051083. 10.1155\/2018\/6051083","journal-title":"Case Rep Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.021","article-title":"Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies","volume":"6","author":"Gouin A","year":"2021","unstructured":"Gouin A, Ribes D, Colombat M, et al.. Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies. Kidney Int Rep. 2021, 6:1015-21. 10.1016\/j.ekir.2021.01.021","journal-title":"Kidney Int Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/123168-scleroderma-renal-crisis-with-thrombotic-microangiopathy-treated-with-eculizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:50Z","timestamp":1707508310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/123168-scleroderma-renal-crisis-with-thrombotic-microangiopathy-treated-with-eculizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.31977","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}